- Home
- OKTA vs INCY Comparison
OKTA vs INCY Comparison
Compare OKTA & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKTA
- INCY
- Stock Information
- Founded
- OKTA 2009
- INCY 1991
- Country
- OKTA United States
- INCY United States
- Employees
- OKTA N/A
- INCY N/A
- Industry
- OKTA Computer Software: Prepackaged Software
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- OKTA Technology
- INCY Health Care
- Exchange
- OKTA Nasdaq
- INCY Nasdaq
- Market Cap
- OKTA 16.6B
- INCY 13.4B
- IPO Year
- OKTA 2017
- INCY 1993
- Fundamental
- Price
- OKTA $92.75
- INCY $72.11
- Analyst Decision
- OKTA Buy
- INCY Buy
- Analyst Count
- OKTA 35
- INCY 20
- Target Price
- OKTA $106.26
- INCY $74.76
- AVG Volume (30 Days)
- OKTA 2.3M
- INCY 1.7M
- Earning Date
- OKTA 03-03-2025
- INCY 02-10-2025
- Dividend Yield
- OKTA N/A
- INCY N/A
- EPS Growth
- OKTA N/A
- INCY N/A
- EPS
- OKTA N/A
- INCY 0.15
- Revenue
- OKTA $2,533,000,000.00
- INCY $4,241,216,999.00
- Revenue This Year
- OKTA $17.06
- INCY $11.81
- Revenue Next Year
- OKTA $7.78
- INCY $10.71
- P/E Ratio
- OKTA N/A
- INCY $486.10
- Revenue Growth
- OKTA 16.84
- INCY 14.76
- 52 Week Low
- OKTA $70.56
- INCY $50.35
- 52 Week High
- OKTA $114.50
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- OKTA 49.06
- INCY 51.77
- Support Level
- OKTA $95.11
- INCY $69.75
- Resistance Level
- OKTA $98.00
- INCY $72.69
- Average True Range (ATR)
- OKTA 3.12
- INCY 2.48
- MACD
- OKTA -0.73
- INCY -0.08
- Stochastic Oscillator
- OKTA 12.78
- INCY 57.46
About OKTA Okta Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.